Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Public ClinicalTrials.gov record NCT04417530. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Open-label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
Study identification
- NCT ID
- NCT04417530
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2020
- Primary completion
- Apr 21, 2024
- Completion
- Apr 21, 2024
- Last update posted
- Mar 2, 2025
2020 – 2024
United States locations
- U.S. sites
- 22
- U.S. states
- 19
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Retina Associates SW, P.C. | Tucson | Arizona | 85710 | — |
| UCLA Jules Stein Eye Institute | Los Angeles | California | 90095 | — |
| Byers Eye Institute at Stanford University | Palo Alto | California | 94303 | — |
| UCHealth Eye Center | Aurora | Colorado | 80045 | — |
| Retina Associates of Florida | Tampa | Florida | 33609 | — |
| Emory Eye Center | Atlanta | Georgia | 30322 | — |
| University of Illinois At Chicago Illinois Eye and Ear Infirmary | Chicago | Illinois | 60612 | — |
| Midwest Eye Institute | Carmel | Indiana | 46290 | — |
| University of Iowa Department of Ophthalmology and Visual Sciences | Iowa City | Iowa | 52242 | — |
| Massachusetts Eye and Ear Infirmary | Boston | Massachusetts | 02114 | — |
| W. K. Kellogg Eye Center, University of Michigan | Ann Arbor | Michigan | 48105 | — |
| Associated Retinal Consultants, PC | Royal Oak | Michigan | 48073 | — |
| Retina Center | Minneapolis | Minnesota | 55404 | — |
| Columbia University Medical Center | New York | New York | 10027 | — |
| Dean McGee Eye Institute | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health & Science University Casey Eye Institute | Portland | Oregon | 97239 | — |
| Wills Eye Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Retina Consultants of Carolina, PA | Greenville | South Carolina | 29605 | — |
| St. Thomas Health / Tennessee Retina, PC | Nashville | Tennessee | 37203 | — |
| Texas Retina Associates | Dallas | Texas | 75231 | — |
| Retina Consultants of Houston | Houston | Texas | 77030 | — |
| University of Wisconsin Dept of Ophthalmology & Visual Sciences | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Uveal Melanoma trials
Other public records listing Uveal Melanoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT06246149: Adjuvant Tebentafusp in High Risk Ocular Melanoma Recruiting
- NCT06932757: Adjuvant Quisinostat in High-Risk Uveal Melanoma Recruiting
- NCT07015190: Neoadjuvant Darovasertib in Primary Uveal Melanoma Recruiting
- NCT05496686: Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma Active, not recruiting
- NCT05524935: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Recruiting
- NCT06075589: Psychoeducation for Uveal Melanoma Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04417530, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 2, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04417530 live on ClinicalTrials.gov.